WELCOME TO SAN ANTONIO AND THE 2019 SAN ANTONIO BREAST CANCER SYMPOSIUM (SABCS)

UT Health Cancer Center, Baylor College of Medicine, and the American Association for Cancer Research (AACR) take great pride in presenting this year's SABCS. We are incredibly excited to have you attend.

The San Antonio Breast Cancer Symposium is the premiere international breast cancer symposium. We hope you will take advantage of every opportunity to expand your knowledge by attending a variety of sessions and networking with the field’s leading professionals. This Symposium is translational and strives to provide state-of-the-art information on the experimental biology, etiology, prevention, diagnosis, and therapy of breast cancer and premalignant breast disease.

The Breast Cancer Symposium format incorporates diverse elements in order to provide maximum scientific exposure and interaction. These elements include plenary lectures, oral abstract presentations, general poster sessions, general spotlight poster discussion sessions, workshops, educational sessions, award lectures, debate, panel and case discussions, selected mini-symposia, basic science, translational, and clinical forums, and a year in review over a 5 day period.

The meeting begins on Tuesday with the Educational Sessions which are an update on advances in the technologies available for translational research. These sessions are to provide people with a better understanding of the talks they hear using the techniques described. They also provide researchers with a guide to the techniques they should be considering for their studies. In general, meeting days begin with poster discussion sessions and a poster session/continental breakfast at 7:00 AM and end with poster discussion sessions and a poster session/reception that concludes at 7:00 PM. Most sessions are consecutive which allows participants to attend all translational sessions. Specific basic science research and clinical research sessions, the educational sessions, poster discussion/poster sessions, and the case discussion/basic science and clinical forums are presented as parallel sessions.

With so many valuable sessions it is hard to attend everything you want. Don’t worry, within 24 hours of a presentation, posters and oral presentations including slides will be made available online at www.sabcs.org.

We are extremely grateful to the Program Planning, Abstract Review, and Abstract Selection Committees for their exceptional work this year in putting together an amazing program featuring prominent speakers from around the world. We urge you to take full advantage of everything the meeting has to offer.

On behalf of the executive committee, we hope you enjoy your week in San Antonio. If there is anything we can do for you, please do not hesitate to ask.

Sincerely,
Kent Osborne, MD      Carlos Arteaga, MD      Virginia Kaklamani, MD

HOW TO CONNECT:
1: In your wireless settings scan for available wireless networks.
2: Open your favorite browser.
3: When symposium welcome page loads you are connected!
PLENARY LECTURE 1: STROMAL CELLS AND MATRIX REMODELING AS ESSENTIAL REGULATORS OF THE TUMOR MICROENVIRONMENT
Ellen Püré, PhD, University of Pennsylvania, Philadelphia, PA

HALL 3, 8:15 AM - 8:45 AM

Ellen Püré, PhD, will discuss how fibroblast activation protein (FAP)-expressing cells and the extracellular matrix regulate tumor and adipose cell behavior in her plenary lecture, “Stromal Cells and Matrix Remodeling as Essential Regulators of the Tumor Microenvironment.” Püré, from the University of Pennsylvania, will present at the Symposium on Wednesday morning.

Several studies show that the initiation, progression, and metastasis is associated with desmplasia, which is characterized by activation of mesenchymal-derived stromal cells and dynamic remodeling of the extracellular matrix. The stromal cell component has subpopulations of cancer-associated fibroblasts (CAF's) and CAF-mediated pathways that regulate tumor progression. Püré plans to focus on the fibroblast activation protein (FAP)-expressing CAFs, which promote tumor progression and are correlated with poorer survival in breast and multiple other cancers.

Preclinical studies showed reductions in tumorigenesis, progression, and metastases in FAP-knockout mouse models of lung, colon, pancreatic, and breast cancer generated using genetic, chimeric antigen receptor (CAR) T cell, or antibody-targeting approaches. Püré and her colleagues also found, unexpectedly, that their FAP-null mouse model became obese following consumption of a high-fat diet, but the obesity was a “healthy” obesity, according to Püré, and not associated with the high-risk, aggressive disease community demonstrated in obesity-associated breast cancer.

“Obesity and [FAP] play a role in modifying connective tissue in a way that allows fat cells to expand, without causing things like insulin resistance associated with ‘risky’ obesity,” said Püré.

Although Püré noted that she and her colleagues plan to pursue the development of a FAP-targeted CAR T cell for clinical use in the future, she said that evaluating the mechanisms of FAP on tumor and adipose cells to identify molecular pathways involved will be the focus of her lecture.

“We got into breast cancer because we wanted to understand the interface between (tumor) microenvironment and environmental factors,” said Püré. “We know there are risk factors (for breast cancer), but what we don’t know is [whether] those effects act directly on the tumor cell, through changes in the microenvironment, or through changes in immunity. We have to step back and look at it at a broader level before tackling it clinically.”

Püré predicted that future research on FAP and other components of the stromal cells and extracellular matrix will be instrumental in guiding development of therapeutics.

“We are learning a lot more about how the connective tissue response to environmental factors puts a tissue at risk for allowing a tumor cell, if it transforms, to survive and grow and eventually promote its metastasis,” said Püré. “Stromal cells and [extracellular] matrix are going to provide a whole plethora of targets that can be used in combination with immune modulators and targeted therapies.”

PRODUCT THEATRE SCHEDULE
EXHIBIT HALL 2
WEDNESDAY, DECEMBER 11
12:30 PM
Integrating Clinical-Pathologic Features with the Recurrence Score® Result to Help Guide Adjuvant Treatment Decisions
Presented by Genomic Health, Inc
2:00 PM
HER2-Positive Early Breast Cancer: Optimizing adjuvant treatment based on response to neoadjuvant therapy
Presented by Genentech, A Member of the Roche Group

THURSDAY, DECEMBER 12
11:00 AM
New Survival Data for a Treatment Option Approved for Patients With HR+, HER2- Metastatic Breast Cancer
© Lilly USA, LLC 2019. All rights reserved. Presented by Lilly Oncology
12:30 PM
Innovative Oral Treatment Options for Patients: HR+/HER2- MBC or gbRCA-Mutated TNBC and HR+/HER2- MBC
Presented by Pfizer Oncology
2:00 PM
Lynparza: An Optimal Targeted Treatment for gbRCAm HER2-Negative Metastatic Breast Cancer
Presented by AstraZeneca
3:30 PM
Advancing the Treatment of TECENTRIQ®, the first cancer immunotherapy approved for the treatment of PD-L1 tTNBC
Presented by Genentech, A Member of the Roche Group

FRIDAY, DECEMBER 13
11:00 AM
Innovative Biomarker Strategies for Translational Medicine and Clinical Practice in Breast Cancer
Presented by NanoString Technologies
12:30 PM
The ONLY Endocrine Biomarker: Presenting New Pivotal Data from the Translational AT1em
Presented by Biotheranostics, Inc
2:00 PM
Two Considerations in HR+/HER2- mBC: The Importance of PIK3CA Mutations and the Arrival of OS Data With a CDK4/6 Inhibitor
Presented by Novartis Oncology

SPECIAL APPRECIATION
SABCS gratefully acknowledges the Breast Cancer Research Foundation for generous support of the AACR Outstanding Investigator Award for Breast Cancer Research and the Susan G. Komen Foundation for their support of the Educational Sessions.

GRANTS
Funding for this conference was made possible (in part) by SR13CA213939-04 from the National Cancer Institute. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by name, commercial practices, or organizations imply endorsement by the US Government.

This activity is supported by educational grants provided by AstraZeneca, Merck, Pfizer, Daichi Sankyo, Eli Lilly, Novartis, and Lilly (for further information concerning Lilly grant funding, visit www.lillygrantoffice.com).
SABCS 2019 SCHOLARSHIP RECIPIENTS

SABCS Basic Science Scholar Award Recipients
For laboratory-based investigators-in-training whose work focuses on the biology of breast cancer and preclinical models of its development and progression.

- B2 adrenergic receptor-mediated signaling regulates the immunosuppressive potential of myeloid-derived suppressor cells
  Hermn Mohammadpour, PhD, Roswell Park Comprehensive Cancer Center, Buffalo, NY
  P3-01-02 Thursday, December 12 5:00 PM

- A joint atlas of single-cell and bulk RNA-seq in metastatic breast cancer allows inference of oncogenic and drug-resistant transcriptional programs in malignant cells and the tumor microenvironment
  Ofir Cohen, PhD, Dana-Farber Cancer Institute, Boston, MA
  P3-02-02 Wednesday, December 12 7:30 PM

  Hakwee Lee, University of British Columbia, Vancouver, Canada
  G36-05 Friday, December 13 4:15 PM

- Risk of radiation induced secondary malignancies in gBRCA carriers following breast cancer therapy
  Shv Schlosser, Tel Aviv University, Tel Aviv, Israel
  P6D-04 Thursday, December 12 5:00 PM

- Molecular signatures of DCIS to invasive progression for basal-like breast cancers: An integrated mouse model and human tumor study
  Aatish Thennavan, University of North Carolina, Chapel Hill, NC
  P6D-09 Thursday, December 12 5:00 PM

SABCS Clinical Scholar Award Recipients
For clinical scientists-in-training who are actively pursuing clinical or clinical/translational research in breast cancer.

- Use of systemic therapy for early stage breast cancer in older adults: results from the Bridging the Age Gap study
  Melissa Edwards, MB ChB, University of Auckland, New Zealand
  P3-08-01 Thursday, December 12 5:00 PM

- Delayed initiation of adjuvant chemotherapy in older women with breast cancer
  Demetria Smith-Graziani, MD, UT MD Anderson Cancer Center, Houston, TX
  P2-14-04 Thursday, December 12 7:00 AM

Arti Hurria Travel Award Recipients
Created in memory of Dr. Arti Hurria and in recognition of her commitment to the mentorship and training of the next generation of geniatric oncologists. For geniatric oncologists-in-training.

- Use of systemic therapy for early stage breast cancer in older adults: results from the Bridging the Age Gap study
  Nicolo Matteo Luca Battisti, MD, PhD, The Royal Marsden
  PAGE 4 2019 SAN ANTONIO BREAST CANCER SYMPOSIUM
  December 10–14, 2019 • San Antonio, Texas, USA
  P2-02-01 Thursday, December 12 7:00 AM

- Polygenic risk stratification among women carrying moderate penetration pathogenic variants in breast cancer predisposition genes: Results from the CARRIERS study
  Mathilde Almekinders, MD, Netherlands Cancer Institute, Amsterdam, Netherlands
  PD3-02 Wednesday, December 12 11:00 PM

- Liquid biopsy methods and machine learning modeling to understand organ tropism and metastatization behavior of metastatic breast cancer
  Lorenzo Genetalia, MD, Northwestern University, Chicago, IL
  P3-10-05 Thursday, December 12 5:00 PM

Colman Scholar Award Recipients
In memory of Dr. Charles A. Colman, co-founder of SABCS, to commemorate the significant contributions he made to oncology medicine. For clinical scientists-in-training.

- Impact of increased mammary adiposity on DCIS progression
  Mathilde Almekinders, MD, Netherlands Cancer Institute, Amsterdam, Netherlands
  P6-15-07 Saturday, December 14 7:00 AM

- Fragility index of trials supporting approval of breast cancer drugs
  Alexandre Desmyers, MD, Princess Margaret Cancer Centre, Toronto, Canada
  P4-15-01 Friday, December 13 7:00 AM

- Genomic profiling of primary and metastatic breast cancer in men
  Joshua Dragga, MD, Memorial Sloan Kettering Cancer Center, New York, NY
  P4-17-01 Friday, December 13 7:00 AM

AACR Associate Member Award Recipients
For presenters of meritorious abstracts who are Associate Members of the American Association for Cancer Research (AACR).

- Breast cancer arising on the left side is biologically more aggressive and has worse outcomes compared to the right side
  Yana Abolou, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY
  P2-09-09 Thursday, December 12 7:00 AM

- Lack of background parenchymal enhancement suppression in breast MRI during neoadjuvant chemotherapy may be associated with inferior treatment response in hormone receptor positive breast cancer
  Natsuoku Onishi, MD, PhD, University of California San Francisco, San Francisco, CA
  PD3-09 Friday, December 13 5:00 PM

- The impact of breast cancer treatment concordance on survival in relation to comorbidity burden
  Melissa Edwards, MB ChB, University of Auckland, New Zealand
  P3-08-02 Thursday, December 12 5:00 PM

- Development and characterization of a first-in-class small molecule inhibitor of PELI1
  Keshav Attegge, MS, UT Health San Antonio, San Antonio, TX
  P3-10-01 Thursday, December 12 5:00 PM

- A dual role of natural killer cells in breast cancer metastasis
  Isaac Chan, MD, PhD, Johns Hopkins University, Baltimore, MD
  P3-01-01 Thursday, December 12 5:00 PM

- Assessment of intratumoral heterogeneity in early stage estrogen receptor (ER) positive breast cancer
  Sofia Mastoraki, PhD, UT MD Anderson Cancer Center, Houston, TX
  P4-06-03 Friday, December 13 7:00 AM

- Fibroblast growth factor receptor 1 associates with promotors genome-wide and regulates gene transcription in ER+/FGFR1-amplified breast cancer trial
  Roshan Soysaman, PhD, City of Hope, Duarte, CA
  PD2-10-01 Wednesday, December 11 5:00 PM

- Application of machine learning to elucidate the biology predicting response in the I-SPY 2 neoadjuvant breast cancer trial
  Malvina Bhattacharya, MD, University of Kentucky, Lexington, KY
  PD2-10-01 Wednesday, December 11 5:00 PM

- Polygenic risk stratification among women carrying moderate penetration pathogenic variants in breast cancer predisposition genes: Results from the CARRIERS study
  Mathilde Almekinders, MD, Netherlands Cancer Institute, Amsterdam, Netherlands
  PD3-02 Wednesday, December 12 11:00 PM

- A novel model to study to metaplastic TNBC
  Kusum Bhatia, MD, City of Hope, Duarte, CA
  PD2-10-01 Wednesday, December 11 5:00 PM

- Comparison of recommendations for germline genetic testing in an uns echoed cohort of patients with breast cancer
  Siddhartha Yadav, MD, Mayo Clinic, Rochester, MN
  P6-08-01 Saturday, December 14 7:00 AM
SABCS 2019 AWARD RECIPIENTS

WILLIAM L. MCGUIRE MEMORIAL LECTURE
The McGuire Award was established in 1993 to honor William L. McGuire, MD, who co-founded the San Antonio Breast Cancer Symposium® in 1977 along with Charles A. Coltman, MD.

What Would Bill Think?
Wednesday, December 11th 1:15 PM – Hall 3

Dr. Joseph Sparano, associate director for clinical research at the Montefiore Einstein Center for Cancer Care, Albert Einstein College of Medicine, New York, is being recognized for a distinguished career marked by his leadership, collaboration, and practice-changing achievements. His work in clinical and translational breast cancer research has improved the lives of numerous patients.

He has played a key role in the design and implementation of numerous clinical trials since joining the ECOG-ACRIN Cancer Research Group (formerly the Eastern Cooperative Oncology Group or ECOG) in 1991. He served as study chair for the recently reported TAILORx trial. This National Cancer Institute-sponsored, multi-center trial enrolled more than 10,000 women with early-stage breast cancer. The results of the TAILORx trial led to the removal of NCCN guidelines, immediately changing clinical practice.

Dr. Sparano’s research on biomarkers of recurrence and prognosis has moved the field forward and led to more effective, personalized treatments for cancer patients. His peers exalt his organizational skills and he is recognized as a committed mentor.

In 2001 he initiated the ECOG Young Investigator Symposium, now an annual event that has provided the opportunity for more than 200 young clinicians to interact with senior investigators and learn about cooperative group research.

WILLIAM L. MCGUIRE MEMORIAL LECTURE

Dr. Joseph Sparano, MD
Montefiore Medical Center
Bronx, NY

SUSAN G. KOMEN® BRINKER AWARD FOR SCIENTIFIC DISTINCTION IN BASIC SCIENCE
Deciphering Stem and Progenitor Cells to Understand Breast Cancer

The Brinker Award for Scientific Distinction in Basic Science will be presented to Jane Visvader, PhD, and Geoffrey Lindeman, MBBS, FRACP, PhD, Joint Heads of the Walter and Eliza Hall Institute’s (WEHI) Stem Cells Division at the Walter and Eliza Hall Institute (WEHI), in Melbourne, Australia. Drs. Visvader and Lindeman have made significant contributions to our understanding of how normal and cancerous cells develop in the breast. Their research has resulted in critical insights about the regulation of normal breast cell growth and breast cancer initiation and progression, including the identification of breast stem cells that give rise to normal breast tissue and the breast cells that are predisposed to becoming cancerous in women with BRCA1 gene mutations.

Jane Visvader, PhD
The Walter and Eliza Hall Institute (WEHI)
Melbourne, Australia

Geoffrey Lindeman, MBBS, FRACP, PhD
The Walter and Eliza Hall Institute (WEHI)
Melbourne, Australia

SUSAN G. KOMEN® BRINKER AWARD FOR SCIENTIFIC DISTINCTION IN CLINICAL RESEARCH
The Molecular Etiology of Luminal-Type Breast Cancer

The Brinker Award for Scientific Distinction in Clinical Research will be presented to Matthew J. Ellis, MB BChir, BSc, PhD, FRCP, Professor of Medicine and Cellular and Molecular Biology, Director of the Lester and Sue Smith Breast Center, and Associate Director for Translational Research at the Dan L. Duncan Cancer Center, Baylor College of Medicine. Dr. Ellis is being honored for his seminal contributions in understanding the genomics of breast cancer and translating this knowledge to the clinic to improve the efficacy of breast cancer treatment. His work to define the genomic landscape of breast cancer, drug resistance mechanisms, and biomarkers for breast cancer prognosis, coupled with his pioneering research in the pre-surgical treatment of breast cancer, has resulted in significant advances that are paving the way for more personalized treatments for breast cancer.

Matthew J. Ellis, MB BChir, BSc, PhD, FRCP
Baylor College of Medicine
Houston, TX

EXHIBITORS
Agenda, Inc
Alamo Breast Cancer Foundation
Ambry Genetics, A Konica Minolta Company
American Association for Cancer Research
Amgen, Inc
AstraZeneca
Athenex Oncology
Biotheranostics, Inc.
Bristol-Myers Squibb
Caris Life Sciences
Cellgene Corporation
Cienna Medical/Merit Medical
Caheres BioSciences
Daichi Sankyo, Inc.
Dan L. Duncan Comprehensive Cancer Center @ Baylor College of Medicine
Datar Cancer Genetics Limited
Dignitana
Eisai, Inc
Elsevier
Elucent Medical, Inc
Encore Medical Education, LLC
Epic Sciences
ESMO - European Society For Medical Oncology
Genentech, A Member of the Roche Group
Genomic Health
Global Breast Cancer Conference Harborside
HealthCare Partners Nevada
Hologic, Inc
The IBC Network Foundation
Immunomedics, Inc
Integrated Oncology
Invicro
Invitae
JAMA Network
Jeunesse Innovations
Lilly Oncology
Lumicell, Inc
MacroGenics, Inc.
Male Breast Cancer Coalition
Med-Care Pharmaceuticals
Medscape Oncology
Menarini Silicon Biosystems
Merck & Co., Inc.
METAArray Research and Support, Inc
Mibo Global Alliance, Inc
Mylan Inc
Myriad Genetic Laboratories, Inc.
NanoString Technologies
NeoGenomics
Novartis Oncology
Obi Pharma USA, Inc
The Oncologist
Paxman USA Inc
Pfizer
Pfizer Oncology Medical
Pfizer Oncology - Ibrance & Talzenna
Philips Molecular Pathway DX
Physician’s Education Resource, LLC
PreludeDx
Puma Biotechnology, Inc.
Radius Health, Inc.
Roche Diagnostics Corporation
R-Pharm US
Research To Practice
Seattle Genetics
Sema4
Sermonyx Pharmaceuticals
SibioTech, Inc.
Society of Surgical Oncology
Spectrum Pharmaceuticals
Stayhealthy Inc.
Syndax Pharmaceuticals
Tactic Medical
Tempus
TerSera Therapeutics
TRIO - Translational Research in Oncology
TxSCCO - Texas Society of Clinical Oncology
UT MD Anderson Cancer Center
VISION RT
Wolters Kluwer
Alamo Breast Cancer Foundation
Alamo Breast Cancer Foundation
American Association for Cancer Research
American Association for Cancer Research
American Association for Cancer Research
American Association for Cancer Research
2019 FOUNDATION, INDUSTRY, & AGENCY SUPPORT

We are proud to acknowledge the following for their contributions to and generous support of our program.

PREMIER

Daiichi-Sankyo
Genentech
Pfizer

ANGEL

AstraZeneca
Biotheranostics, Inc

PATRON

Seattle Genetics

MAJOR SUPPORTERS

Bristol-Myers Squibb
NanoString Technologies

MAJOR SUPPORTERS

Amgen, Inc
Athenex Oncology
ImmunoMedics

CONTRIBUTORS

Agendia, Inc
Alamo Breast Cancer Foundation
American Association for Cancer Research
Baylor College of Medicine

DONORS

Ambry Genetics, A Konica Minolta Company
BRAVE Coalition Foundation
Breast Cancer Action

Cianna Medical/Merit Medical
Coherus BioSciences, Inc
Datar Cancer Genetics Limited
Dignitana
Elucent Medical, Inc
ESMO - European Society for Medical Oncology
Global Breast Cancer Conference
HealthCare Partners Nevada

Hologic, Inc
The IBC Network Foundation
Integrated Oncology

Invicro
JAMA Network
Lumicell, Inc
Male Breast Cancer Coalition
Medscape Oncology
Menarini Silicon Biosystems
NeoGenomics

OBI Pharma USA, Inc
Paxman USA Inc.
Philips Molecular Pathway DX

Puma Biotechnology, Inc
Radius Health

Spectrum Pharmaceuticals
Stayhealthy Inc
Syndax Pharmaceuticals
Wolters Kluwer

*AT PRESS TIME